OPK - OPKO Health, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Miami,
United States
Type: Equity
OPK price evolution
OPK
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $40.58 | $75.64 | $95.88 | |
| Short term investments | ||||
| Net receivables | $138.66 | $105.31 | $111.37 | $123.38 |
| Inventory | $59.41 | $60.15 | $59.37 | $65.7 |
| Total current assets | $629.64 | $357.98 | $391.3 | $309.48 |
| Long term investments | $101.49 | $40.99 | $16.08 | |
| Property, plant & equipment | $135.08 | $128.39 | $127.5 | $143.52 |
| Goodwill & intangible assets | $1189.22 | $1210.65 | $1338.54 | |
| Total noncurrent assets | $1621.89 | $1582.71 | $1702.22 | |
| Total investments | $101.49 | $40.99 | $16.08 | |
| Total assets | $2256.1 | $1979.87 | $1974.02 | $2011.7 |
| Current liabilities | ||||
| Accounts payable | $62.72 | $82.24 | $71.16 | $69.68 |
| Deferred revenue | ||||
| Short long term debt | $33.92 | $34.73 | $40.29 | |
| Total current liabilities | $211.66 | $219.55 | $204.34 | $200.05 |
| Long term debt | $432.27 | $225.57 | $374.04 | $268.46 |
| Total noncurrent liabilities | $365 | $516.87 | $422.43 | |
| Total debt | $259.49 | $408.77 | $308.75 | |
| Total liabilities | $852.69 | $584.55 | $721.21 | $622.48 |
| Shareholders' equity | ||||
| Retained earnings | -$2079.04 | -$2103.93 | -$2093.62 | -$2011.79 |
| Other shareholder equity | -$39.61 | -$46.65 | -$45.2 | -$38.03 |
| Total shareholder equity | $1395.32 | $1252.81 | $1389.22 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $95.88 | $153.19 | $134.71 | $72.21 |
| Short term investments | ||||
| Net receivables | $123.38 | $148.61 | $259.64 | $286.31 |
| Inventory | $65.7 | $74.06 | $86.5 | $132.34 |
| Total current assets | $309.48 | $394.52 | $823.01 | $523.18 |
| Long term investments | $16.08 | $28.08 | $10.73 | $15.73 |
| Property, plant & equipment | $143.52 | $121.6 | $123.95 | $178.29 |
| Goodwill & intangible assets | $1338.54 | $1419.37 | $842.28 | $1155.6 |
| Total noncurrent assets | $1702.22 | $1772.73 | $1576.7 | $1949.88 |
| Total investments | $16.08 | $28.08 | $10.73 | $15.73 |
| Total assets | $2011.7 | $2167.26 | $2399.72 | $2473.06 |
| Current liabilities | ||||
| Accounts payable | $69.68 | $66.99 | $82.04 | $100.88 |
| Deferred revenue | ||||
| Short long term debt | $40.29 | $48.22 | $26.32 | $33.73 |
| Total current liabilities | $200.05 | $213.48 | $330.01 | $375.48 |
| Long term debt | $268.46 | $226.56 | $221.03 | $251.75 |
| Total noncurrent liabilities | $422.43 | $392.13 | $384.58 | $426.03 |
| Total debt | $308.75 | $286.55 | $247.35 | $285.48 |
| Total liabilities | $622.48 | $605.61 | $714.59 | $801.51 |
| Shareholders' equity | ||||
| Retained earnings | -$2011.79 | -$1822.92 | -$1511.98 | -$1481.83 |
| Other shareholder equity | -$38.03 | -$43.32 | -$30.5 | -$4.22 |
| Total shareholder equity | $1389.22 | $1561.65 | $1685.13 | $1671.55 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $182.19 | $173.69 | ||
| Cost of revenue | $130.53 | $131.62 | ||
| Gross Profit | $51.65 | $42.07 | ||
| Operating activities | ||||
| Research & development | $24.08 | $21.94 | ||
| Selling, general & administrative | $68.82 | $70.17 | ||
| Total operating expenses | $113.32 | $113.54 | ||
| Operating income | -$61.67 | -$71.47 | ||
| Income from continuing operations | ||||
| EBIT | -$2.4 | -$75.5 | ||
| Income tax expense | -$0.28 | -$1.35 | ||
| Interest expense | $8.18 | $7.69 | ||
| Net income | ||||
| Net income | -$10.3 | -$81.84 | ||
| Income (for common shares) | -$10.3 | -$81.84 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $863.5 | $1004.2 | $1774.72 | $1435.41 |
| Cost of revenue | $545.37 | $715.98 | $1193.19 | $894.41 |
| Gross Profit | $318.13 | $288.22 | $581.52 | $541 |
| Operating activities | ||||
| Research & development | $89.59 | $73.89 | $76.85 | $75.32 |
| Selling, general & administrative | $300.56 | $372.67 | $468.86 | $355.57 |
| Total operating expenses | $475.15 | $514.47 | $562.77 | $483.29 |
| Operating income | -$157.02 | -$226.25 | $18.75 | $57.71 |
| Income from continuing operations | ||||
| EBIT | -$170.92 | -$379.85 | $4.23 | $70.14 |
| Income tax expense | $4.44 | -$63.5 | $15.49 | $17.62 |
| Interest expense | $13.51 | $12.06 | $18.88 | $21.93 |
| Net income | ||||
| Net income | -$188.86 | -$328.4 | -$30.14 | $30.59 |
| Income (for common shares) | -$188.86 | -$328.4 | -$30.14 | $30.59 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$10.3 | -$81.84 | -$66.48 | |
| Operating activities | ||||
| Depreciation | $24.15 | $25.82 | $25.98 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.61 | $2.59 | $2.67 | |
| Total cash flows from operations | -$26.43 | -$35.57 | -$38.29 | |
| Investing activities | ||||
| Capital expenditures | -$7.16 | -$4.39 | -$1.42 | |
| Investments | ||||
| Total cash flows from investing | $236.23 | -$7.16 | -$4.39 | -$1.42 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.21 | -$50 | $0 | |
| Net borrowings | -$1.91 | $70.61 | -$3.75 | |
| Total cash flows from financing | $224.64 | -$2.12 | $20.61 | -$3.75 |
| Effect of exchange rate | $2.4 | $0.65 | -$0.89 | $0.72 |
| Change in cash and equivalents | $324.18 | -$35.06 | -$20.24 | -$42.74 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$188.86 | -$328.4 | -$30.14 | $30.59 |
| Operating activities | ||||
| Depreciation | $105.3 | $108.66 | $78.72 | $85.36 |
| Business acquisitions & disposals | -$1.76 | -$4 | ||
| Stock-based compensation | $11.41 | $18.51 | $13.63 | $8.95 |
| Total cash flows from operations | -$28.2 | -$95.19 | $38.34 | $39.48 |
| Investing activities | ||||
| Capital expenditures | -$13.56 | -$22.63 | $33.87 | -$33.44 |
| Investments | -$4.64 | $115.42 | $6.08 | $15.11 |
| Total cash flows from investing | -$18.2 | $91.04 | $35.95 | -$18.33 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.27 | -$0.77 | $1.08 | $0.76 |
| Net borrowings | -$11.03 | $23.75 | -$11.43 | -$35.83 |
| Total cash flows from financing | -$11.3 | $22.97 | -$10.35 | -$35.08 |
| Effect of exchange rate | $0.39 | -$0.34 | -$1.44 | $0.69 |
| Change in cash and equivalents | -$57.31 | $18.48 | $62.5 | -$13.24 |
News
Fundamentals
| Market cap | $1.04B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 682.48M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.45 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.97 |
| Quick ratio | 2.69 |